Request Legal Help Now - Free

Advertisement
LAWSUITS NEWS & LEGAL INFORMATION

FDA Warns of Risk of Eosinophilic Pneumonia with Daptomycin


Washington, DC: The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia during treatment with Cubicin (daptomycin), an intravenous antibacterial drug indicated for use in treatment of serious skin infections and bloodstream infections.

Eosinophilic pneumonia is a rare but serious condition where a type of white blood cell (eosinophil) fills the lungs. Symptoms of eosinophilic pneumonia include fever, cough, shortness of breath, and difficulty breathing. Eosinophilic pneumonia may lead to progressive respiratory failure and is potentially fatal if not quickly recognized and appropriately managed. The FDA has reviewed published case reports of Cubicin-associated eosinophilic pneumonia and conducted a review of post-marketing adverse event reports from the FDA's Adverse Event Reporting System. FDA's review identified 7 cases of eosinophilic pneumonia between 2004 and 2010 that were most likely associated with Cubicin.

Based on these reviews, the FDA determined that eosinophilic pneumonia can be associated with Cubicin use and requested that the manufacturer of Cubicin include this information in the Warnings and Precautions and Adverse Reactions, Post-Marketing Experience sections of the drug label.

Legal Help

If you or a loved one has suffered illness or an adverse event relating to this issue, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Published on Jul-29-10


READER COMMENTS

Posted by

on
Serious complications from Cubicin infusions in May 2019.. lungs have not recovered. Pulmonary functions are severely compromised.

Posted by

on
My husband is recovering from eosinophilic pneumonia due to the use of Cubicin. Any action being taken because of this problem? He was in the hospital for six days and is still being treated for this sickness
Linda Sloan

ADD YOUR COMMENT ON THIS ISSUE

Please read our comment guidelines before posting.


Note: Your name will be published with your comment.


Your email will only be used if a response is needed.

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.

Request Legal Help Now! - Free